|View printer-friendly version|
|September 18, 2005 11:44 a.m.|
|Teva Announces Tentative Approval of Ribavirin Tablets|
Jerusalem, Israel, September 18, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Ribavirin Tablets, 200 mg. Final approval is expected upon expiry of brand exclusivity in December 2005.